Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$13.83 +0.2%	$18.24	$13.66 ▼ $30.41	$1.90B	0.92	1.33 million shs	362,827 shs
ROIV Roivant Sciences	$10.38 -1.0%	$10.76	$9.96 ▼ $13.06	$7.40B	1.26	5.18 million shs	1.62 million shs
RVMD Revolution Medicines	$37.59 -1.3%	$40.38	$29.55 ▼ $62.40	$6.98B	1.46	1.30 million shs	317,753 shs
SRPT Sarepta Therapeutics	$70.53 -1.8%	$103.61	$70.43 ▼ $173.25	$6.84B	0.79	1.25 million shs	386,670 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-0.93%	-8.67%	-29.34%	-27.22%	-51.92%
ROIV Roivant Sciences	+0.38%	-4.47%	-0.10%	-11.19%	-3.32%
RVMD Revolution Medicines	+1.01%	-1.01%	-7.84%	-13.82%	+20.11%
SRPT Sarepta Therapeutics	-1.47%	-2.23%	-32.86%	-40.90%	-44.86%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.4679 of 5 stars	3.3	1.0	3.4	2.5	2.5	0.0
ROIV Roivant Sciences	2.3641 of 5 stars	3.5	1.0	0.0	3.2	3.3	0.0
RVMD Revolution Medicines	4.1595 of 5 stars	4.5	0.0	4.7	2.3	2.5	0.0
SRPT Sarepta Therapeutics	4.8364 of 5 stars	4.4	3.0	4.2	2.9	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.60	Moderate Buy	$41.44	199.63% Upside
ROIV Roivant Sciences	3.00	Buy	$17.10	64.82% Upside
RVMD Revolution Medicines	3.08	Buy	$66.31	76.40% Upside
SRPT Sarepta Therapeutics	2.83	Moderate Buy	$167.41	137.38% Upside

Current Analyst Ratings Breakdown

Latest ARWR, ROIV, SRPT, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/20/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$105.00 ➝ $80.00
3/19/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$124.00 ➝ $99.00
3/19/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell	$75.00 ➝ $75.00
3/18/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00 ➝ $202.00
3/18/2025	SRPT Sarepta Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$163.00 ➝ $163.00
3/7/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$105.00
3/4/2025	ROIV Roivant Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
3/3/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $73.00
2/27/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
2/27/2025	RVMD Revolution Medicines	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
2/27/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $59.00

(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$2.50M	759.75	N/A	N/A	$1.54 per share	8.98
ROIV Roivant Sciences	$122.59M	60.39	N/A	N/A	$7.76 per share	1.34
RVMD Revolution Medicines	$742K	9,418.42	N/A	N/A	$11.09 per share	3.39
SRPT Sarepta Therapeutics	$1.90B	3.60	N/A	N/A	$9.19 per share	7.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$5.17	N/A	N/A	N/A	N/A	-236.60%	-64.09%	5/8/2025 (Estimated)
ROIV Roivant Sciences	$4.35B	-$0.15	N/A	N/A	N/A	-119.54%	-14.05%	-12.81%	5/29/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$3.57	N/A	N/A	N/A	N/A	-33.67%	-30.08%	5/6/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	$2.28	56.42	6.45	N/A	7.43%	11.00%	3.35%	4/29/2025 (Estimated)

Latest ARWR, ROIV, SRPT, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
2/26/2025	Q4 2024	RVMD Revolution Medicines	-$1.01	-$1.12	-$0.11	-$1.12	$0.35 million	N/A
2/10/2025	Q1 2025	ARWR Arrowhead Pharmaceuticals	-$0.42	-$1.39	-$0.97	-$1.39	$19.05 million	N/A
2/10/2025	Q3 2025	ROIV Roivant Sciences	-$0.24	-$0.20	+$0.04	$0.23	$4.75 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
ROIV Roivant Sciences	N/A	37.91	37.91
RVMD Revolution Medicines	N/A	14.24	14.24
SRPT Sarepta Therapeutics	0.93	3.84	3.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
ROIV Roivant Sciences	64.76%
RVMD Revolution Medicines	94.34%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
ROIV Roivant Sciences	7.90%
RVMD Revolution Medicines	8.00%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	137.32 million	120.68 million	Optionable
ROIV Roivant Sciences	860	713.55 million	657.18 million	Optionable
RVMD Revolution Medicines	250	185.91 million	154.76 million	Optionable
SRPT Sarepta Therapeutics	1,314	97.03 million	88.17 million	Optionable

ARWR, ROIV, SRPT, and RVMD Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 28 at 10:00 AM | accessnewswire.com

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

March 28 at 10:00 AM | accessnewswire.com

Corient Private Wealth LLC Invests $786,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

March 28 at 3:51 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 27 at 10:00 AM | accessnewswire.com

Corebridge Financial Inc. Has $13.26 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

March 27 at 4:49 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 26 at 8:00 PM | globenewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week Low - What's Next?

March 26 at 5:12 PM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation

March 26 at 10:00 AM | accessnewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Teacher Retirement System of Texas

March 26 at 4:02 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation

March 25 at 10:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 25 at 10:00 AM | prnewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Lifted by Emerald Advisers LLC

March 25 at 5:37 AM | marketbeat.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Reduced by Signaturefd LLC

March 25 at 3:53 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 24, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect

March 24, 2025 | accessnewswire.com

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

March 24, 2025 | zacks.com

Simplify Asset Management Inc. Cuts Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

March 24, 2025 | marketbeat.com

StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta

March 23, 2025 | genengnews.com

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

March 23, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 23, 2025 | accessnewswire.com

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

March 23, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR, ROIV, SRPT, and RVMD Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$13.83 +0.03 (+0.23%)

As of 01:31 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Roivant Sciences NASDAQ:ROIV

$10.38 -0.11 (-1.00%)

As of 01:31 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Revolution Medicines NASDAQ:RVMD

$37.59 -0.51 (-1.34%)

As of 01:31 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Sarepta Therapeutics NASDAQ:SRPT

$70.53 -1.29 (-1.79%)

As of 01:31 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time